Updates are available Correction dated 2025-10-09
Click to view Correction: https://doi.org/10.1038/s41467-025-64877-y
-
Authors
Taubenheim, Jan https://orcid.org/0000-0001-7283-1768
Kadibalban, A. Samer
Zimmermann, Johannes https://orcid.org/0000-0002-5041-1954
Taubenheim, Claudia
Tran, Florian https://orcid.org/0000-0002-3735-9872
Schreiber, Stefan
Rosenstiel, Philip https://orcid.org/0000-0002-9692-8828
Aden, Konrad https://orcid.org/0000-0003-3482-7316
Kaleta, Christoph https://orcid.org/0000-0001-8004-9514
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 19 May 2025
First Online: 2 June 2025
Change Date: 9 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-64877-y
Competing interests
: S.S. received personal fees for lectures and consultancy from: AbbVie, Amgen, Arena, Biogen, Bristol Meyers Squibb, Celgene, Celltrion, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Protagonist, Provention Bio, Roche, Sandoz/Hexal, Shire, Takeda, and Ventyx. F.T. received speaker’s fees from Abbvie, Bristol-Myers-Squibb, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Janssen/J&J, Takeda, and funding from Sanofi/Regeneron. KA received consulting fee from Abbvie, J&J, Takeda, Immunowissen, Dr. Falk Pharma, Ferring Pharmaceuticals. All other authors declare no competing interests.
: All research complied with relevant ethical regulations, and usage of human tissue material and transcriptome data was approved by the ethics committee of the Medical Faculty of Kiel University (A156/03, A124/14).
